What is Precision?
Precision Neuroscience operates at the intersection of advanced engineering and clinical neurology, focusing on the development of brain-computer interface (BCI) systems. The company is dedicated to creating a seamless digital connection with the human brain through minimally invasive surgical approaches. Its core product suite includes implantable hardware and sophisticated software systems designed to address a spectrum of neurological and neuropsychiatric conditions, including paralysis, epilepsy, and cognitive impairment. By prioritizing clinical safety and efficacy, Precision is carving out a significant market position within the burgeoning neurotech landscape, aiming to provide transformative therapeutic solutions for patients with limited treatment options.
How much funding has Precision raised?
Precision has raised a total of $405M across 4 funding rounds:
Series A
$12M
Series B
$41M
Series C
$102M
Series D
$250M
Series A (2021): $12M with participation from Steadview Capital and B Capital Group
Series B (2023): $41M led by Mubadala GE Capital PJSC, Forepont Capital Partners, Alumni Ventures, and Draper Associates
Series C (2024): $102M supported by B Capital Group and General Equity Holdings
Series D (2026): $250M featuring Pershing Square, Duquesne Family Office, JSL Health Capital, Invus, Mubadala Capital, Hitachi Ventures, ARK Investment Management, Korea Investment Partners Us, and B Capital Group
Key Investors in Precision
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors.
Hitachi Ventures
Hitachi Ventures GmbH is a corporate venture firm that partners with ambitious founders to drive world-changing innovations across four core themes: Digital, Industrial, Environment, and Healthcare.
ARK Investment Management
ARK Invest is a global asset manager that specializes in thematic investing focused on disruptive innovation, targeting companies expected to lead in transformative technologies.
What's next for Precision?
With the successful closure of its latest funding round, Precision is poised to transition into a phase of rapid clinical expansion and commercial readiness. The strategic capital will likely be deployed to enhance the company's manufacturing capabilities for its implantable hardware and to support the rigorous clinical trials required for regulatory approval. Furthermore, the involvement of specialized healthcare investors suggests a focus on accelerating the path to market for its neural interface platforms. As the company scales, it will likely prioritize the integration of its technology into standard clinical workflows, aiming to establish its BCI systems as a foundational tool in modern neurology and patient care.
See full Precision company page
